Metabasis Just the Latest to Come Up Short in IPO Market
Prices the Reflect Nature of Firms With Products Years Away From Market


Several San Diego biotech companies completing their initial public offerings at below the expected price range suggests that IPO hopefuls with drugs in early-stage development will also face challenges when pricing their deals, according to one analyst...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $99